Related Experiment Video
Updated: Feb 23, 2026
A Melanoma Patient-Derived Xenograft Model
Published on: May 20, 2019
Patient-Derived Orthotopic Xenograft (PDOX) Models of Melanoma
1AntiCancer Inc., 7917 Ostrow Street, San Diego, CA 92111, USA. all@anticancer.com.
Abstract:
Metastatic melanoma is a recalcitrant tumor. Although "targeted" and immune therapies have been highly touted, only relatively few patients have had durable responses. To overcome this problem, our laboratory has established the melanoma patient-derived orthotopic xenograft (PDOX) model with the use of surgical orthotopic implantation (SOI). Promising results have been obtained with regard to identifying effective approved agents and experimental therapeutics, as well as combinations of the two using the melanoma PDOX model.
Insights
Metastatic melanoma remains difficult to treat. A new patient-derived xenograft model using surgical orthotopic implantation shows promise for identifying effective melanoma therapies.
Area of Science:
- Oncology
- Cancer Research
- Melanoma Research
Background:
- Metastatic melanoma is a challenging cancer with limited durable treatment responses.
- Current targeted and immune therapies benefit only a subset of patients.
- Novel therapeutic strategies are needed to improve outcomes for melanoma patients.
Purpose of the Study:
- To establish and validate a melanoma patient-derived orthotopic xenograft (PDOX) model.
- To utilize the PDOX model for identifying effective therapeutic agents against metastatic melanoma.
- To explore the potential of combining approved and experimental treatments within this model.
Main Methods:
- Surgical orthotopic implantation (SOI) was used to create the melanoma PDOX model.
- The model was employed to test various approved and experimental therapeutic agents.
- Combinatorial treatment strategies were evaluated in the PDOX model.
Main Results:
- The melanoma PDOX model demonstrated promising results in therapeutic evaluations.
- The model facilitated the identification of potentially effective agents for melanoma treatment.
- The model was effective in assessing combinations of therapies.
Conclusions:
- The melanoma patient-derived orthotopic xenograft (PDOX) model is a valuable tool for preclinical cancer research.
- This model aids in the discovery of effective treatments for metastatic melanoma.
- The PDOX model supports the development of novel therapeutic approaches for recalcitrant melanoma.
